BRETHAIRE Drug Patent Profile
✉ Email this page to a colleague
When do Brethaire patents expire, and when can generic versions of Brethaire launch?
Brethaire is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in BRETHAIRE is terbutaline sulfate. There are seven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the terbutaline sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Brethaire
A generic version of BRETHAIRE was approved as terbutaline sulfate by IMPAX LABS on June 26th, 2001.
US Patents and Regulatory Information for BRETHAIRE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | BRETHAIRE | terbutaline sulfate | AEROSOL, METERED;INHALATION | 018762-001 | Aug 17, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for BRETHAIRE
See the table below for patents covering BRETHAIRE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 286964 | ⤷ Start Trial | |
| Austria | 287678 | ⤷ Start Trial | |
| Austria | 287679 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
